With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...
Many Americans support prohibiting commercials for prescription drugs on television. But enacting that ban could be ...
Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span ...
As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...
Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...
The Growing Market for Weight Loss Treatments: Innovation, Patents, and the Future of GLP-1 Agonists
In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...
Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of ...
Study urges industry to be more transparent and fairer in selecting speakers, and to recruit more women to steering ...
Wen Shuhao helped speed up the development of Pfizer’s Covid oral drug, Paxlovid. Now the chairman of Xtalpi wants to help ...
Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...
A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback